Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is a healthcare service provider with an established drug development company in the area of biopharmaceutical development, focused on metabolic and endocrine disorders. The company's multiple avenues to drive adoption, expanding access through alternative PBM relationships, and a single molecule strategy across oral and injectable formats represent important differentiators for VK2735, VK2809, and VK0214. With a strong cash runway and openness to BD discussions, Viking Therapeutics is well positioned to maintain strategic flexibility while advancing its pipeline.

Bears say

Viking Therapeutics is facing legal challenges and difficulties in advancing their product due to disputes with LGND. Their products, although promising, face competition in development and on the market, as well as potential barriers to entry due to required liver biopsies in Phase 3. Their current cash balance and upcoming Phase 1 study for VK3019 may provide some short-term support, but long-term success is uncertain.

Viking Therapeutics (VKTX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Viking Therapeutics (VKTX) has a Strong Buy consensus rating as of Sep 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.